Abrégé

The present invention relates to a composition containing a plant extract of the genus Philadelphus as an active ingredient, for the prevention, alleviation, or treatment of tuberculosis. The plant extract of the genus Philadelphus significantly reduces the number of Mycobacterium tuberculosis in (in vivo samples of) mice as well as macrophages derived from mouse bone marrow infected with Mycobacterium tuberculosis, and exhibits synergistic effects on the reduction of Mycobacterium tuberculosis when co-administered with an antituberculosis agent, and thus the plant extract of the genus Philadelphus of present invention may be usefully employed as an antituberculosis agent.

Classes IPC  ?

• A61K 36/185 - Magnoliopsida (dicotylédones)
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur 
• A61P 31/06 - Agents antibactériens pour le traitement de la tuberculose
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

Disclosed are a method and apparatus for assessing a cognitive function using brain waves. The method for assessing a cognitive function includes the steps of: measuring event-related potential (ERP) signals generated in each of the left and right prefrontal lobes of a user by using a tool for assessing a cognitive function; calculating a phase-locking value (PLV) between the ERP signals; and evaluating the cognitive function of the user by means of the PLV between the ERP signals.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
• A61B 5/369 - Modalités, c. à d. méthodes diagnostiques spécifiques Électroencéphalographie [EEG]
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux

Abrégé

The present invention relates to a composition for improving memory and preventing, alleviating or treating cognitive impairment, containing an Orixa japonica extract as an active ingredient. The Orixa japonica extract of the present invention has an excellent neuroprotective effect and, in particular, the neuroprotective effect of an Orixa japonica leaf extract is remarkably better than that of an Orixa japonica stem extract, and memory and cognitive function are improved by administering the Orixa japonica leaf extract to an animal model in scopolamine-induced cognitive decline, and thus the present invention can be effectively used as a health functional food for improving memory and cognitive function disorders and as a medicine and a feed additive for preventing, alleviating or treating degenerative brain diseases.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/758 - Zanthoxylum, p.ex. clavelier
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

A composition for preventing, ameliorating or treating a respiratory disease includes fermented Centella asiatica extract as effective component. The composition is effective in, in bronchial epithelial cells as respiratory cells, reducing the production amount of the inflammatory chemokine RANTES, protecting damaged cells induced by LPS, and reducing the expression level of the inflammatory cytokine IL-6, and it can also reduce the neutrophil count and regulate the expression level of inflammatory cytokines or chemokines in an animal model of lung injury. Accordingly, it can be advantageously used for a functional health food for preventing or ameliorating a respiratory disease, or a pharmaceutical product for preventing or treating a respiratory disease.

Classes IPC  ?

• A61K 36/23 - Apiaceae ou Umbelliferae (famille de la carotte), p.ex. aneth, cerfeuil, coriandre ou cumin
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 35/744 - Bactéries lactiques, p.ex. entérocoques, pédiocoques, lactocoques, streptocoques ou leuconostoques
• A61K 35/747 - Lactobacilles, p.ex. L. acidophilus ou L. brevis
• A61K 36/06 - Champignons, p.ex. levures
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

FNDC1, COL3A1, CX3CR1, SLC16A5, EPM2A, SLC35B3, PRTFDC1, CSRNP2, CCL16, HOXB4, GVINP1, LOC339874, MTRNR2L1LOC148709LOC148709, as an active ingredient.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/92 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des lipides, p.ex. le cholestérol
• G01N 30/72 - Spectromètres de masse

Abrégé

The present invention relates to a blood circulation improvement composition containing a Capsicum annuum by-product extract as an active ingredient. A Capsicum annuum by-product, specifically, a Capsicum annuum leaf or Capsicum annuum branch extract, has an excellent platelet aggregation inhibitory effect and, in particular, the platelet aggregation inhibitory effect of an ethanol extract is superior to that of a water extract, and thus the composition of the present invention, containing a Capsicum annuum by-product extract as an active ingredient, can be effectively used as a component of a therapeutic agent for thrombosis, an antithrombotic health functional food, and an antithrombotic herbal composition.

Classes IPC  ?

• A61K 36/81 - Solanaceae (famille de la pomme de terre), p.ex. tabac, Solanum ptycanthum, tomate, belladone, poivron ou datura
• A61P 7/02 - Agents antithrombotiques; Anticoagulants; Anti-agrégants plaquettaires
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

The present invention relates to a composition comprising a Dolichos lablab Linne extract as an active ingredient for the prevention, amelioration or treatment of allergic respiratory diseases. Specifically, in an allergic rhinitis-induced animal model, a Dolichos lablab Linne extract exhibited the effects of ameliorating symptoms of sneezing and nose scratching, reducing serum levels of IgE, histamine, and IL-13 increased by induced rhinitis, and inhibiting the infiltration of immune cells such as eosinophils, macrophages, and lymphocytes into nasal lavage fluid. Additionally, having excellent effects in inhibiting the production of Th2 cytokines and histamine, chikusetsusaponin IVa isolated from the Dolichos lablab Linne extract can be advantageously used in health functional foods and pharmaceuticals for allergic respiratory diseases including allergic rhinitis.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23P 10/00 - Mise en forme ou traitement des produits alimentaires caractérisés par les produits
• A61K 36/48 - Fabaceae ou Leguminosae (famille du pois ou des légumineuses); Caesalpiniaceae; Mimosaceae; Papilionaceae
• A61P 11/02 - Agents rhinologiques, p.ex. décongestionnants
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

The present invention relates to a composition for the prevention, amelioration, or treatment of gastrointestinal diseases, comprising a Cucumis melo L. extract as an active ingredient, wherein the administration of the Cucumis melo L. extract significantly reduces a gastric lesion index due to gastric mucosal damage, reduces histamine content, which in gastric irritation or inflammatory conditions leads to high acid secretion and mucosal damage, decreases the gene expression of inflammatory cytokines in the gastric mucosa, and also increases the gene expression of proteins with antioxidant effects and proteins with gastro-protective functions in the gastric mucosa, and therefore the present invention may be useful as a medicine, health functional food, or feed additive for gastrointestinal diseases caused by gastric mucosal damage.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23P 10/00 - Mise en forme ou traitement des produits alimentaires caractérisés par les produits
• A23L 19/00 - Produits à base de fruits ou de légumes; Leur préparation ou leur traitement
• A61K 36/42 - Cucurbitaceae (famille du concombre)
• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p.ex. antiacides, antisécrétoires, protecteurs de la muqueuse
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

The present invention relates to a tongue image capturing system that can capture frontal and lateral images of the tongue by using a smartphone or a web camera as a frontal camera and a lateral camera, and analyze the images, thereby enabling the diagnose of the tongue without implementing a separate complex device as a tongue diagnosis device.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
• G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p.ex. l’édition

Abrégé

A composition for inhibiting proliferation of tumor comprising Rubus coreanus extract as effective component. It was found that the Rubus coreanus extract binds to PD-L1 present on the surface of cancer cells, thus blocking the interaction between cancer cells and PD-1 on the surface of T cells to activate T cells and exhibit an inhibitory effect on tumor proliferation, and it was also found that the Rubus coreanus extract shows an excellent anti-tumor immune activity in humanized PD-1 animal model induced with MC38 colorectal cancer expressing human PD-L1 and also a synergistic effect when co-administered with anti-cancer agents.

Classes IPC  ?

• A61K 36/73 - Rosaceae (famille de la rose), p.ex. fraise, aronia, mûre ou pyracantha
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur 
• A61P 35/00 - Agents anticancéreux
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Abrégé

The present invention relates to a composition for preventing, ameliorating, or treating cognitive dysfunction, containing a dopamine production inhibitor or a dopamine receptor antagonist and, more specifically, provides a composition for preventing, ameliorating, or treating cognitive dysfunction, a composition for improving learning ability or memory, and/or a composition for ameliorating cognitive decline, which can improve cognitive ability, short-term memory, spatial working memory, learning ability, etc. by inhibiting dopamine production or blocking dopamine receptors. In addition, provided is a method of screening for substances effective in preventing, ameliorating, or treating cognitive dysfunction, improving learning ability and memory, and ameliorating cognitive decline, by screening for substances that inhibit dopamine production in animal models in which cognitive dysfunction or cognitive decline is induced due to increased dopamine levels, or in skin cells in which dopamine secretion is increased.

Classes IPC  ?

• A61K 31/4422 - 1,4-Dihydropyridines, p.ex. nifédipine, nicardipine
• A61K 31/407 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des systèmes hétérocycliques, p.ex. kétorolac, physostigmine
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A23L 33/10 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs
• A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
• A61Q 19/00 - Préparations pour les soins de la peau
• A01K 67/00 - NÉCESSITÉS COURANTES DE LA VIE ÉLEVAGE; CHASSE; PIÉGEAGE; PÊCHE ÉLEVAGE; AVICULTURE; APICULTURE; PISCICULTURE; PÊCHE; OBTENTION D'ANIMAUX, NON PRÉVUE AILLEURS; NOUVELLES RACES D'ANIMAUX Élevage ou obtention d'animaux, non prévus ailleurs; Nouvelles races d'animaux
• C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
• G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique

Abrégé

The present invention relates to a composition for preventing or treating cognitive dysfunction or memory impairment related diseases, including an extract of Ligustrum foliosum Nakai. The extract of Ligustrum foliosum Nakai of the present invention exhibits nerve cell protection, apoptosis-inhibitory effects, and cognitive function improvement effects, and thus can be useful as a therapeutic agent for cognitive dysfunction or memory impairment related diseases.

Classes IPC  ?

• A61K 36/638 - Ligustrum, p.ex. troène
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

OOOOOOOO-glucoside represented by formula 2 below.

Classes IPC  ?

• C07H 17/07 - Benzo[b]pyranones-4
• C07H 1/08 - Séparation; Purification à partir de produits naturels
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61K 36/185 - Magnoliopsida (dicotylédones)
• A61P 35/00 - Agents anticancéreux
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

The present invention relates to an immunoenhancing composition that contains colored rice extract as an active ingredient. Specifically, the colored rice extract of the present invention, which is prepared from colored rice obtained from a mutant rice plant (KCTC 18500P) capable of producing seeds with a yellow bran layer, has the excellent effect of proliferating macrophages and thus can be advantageously utilized in health functional food compositions for enhancing immunity, animal feed additives for boosting immunity, or pharmaceutical compositions for the prevention and treatment of diseases caused by immune deficiency.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/899 - Poaceae ou Gramineae (famille des céréales), p.ex. bambou, blé ou canne à sucre
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 1/02 - Préparations stomatologiques, p.ex. médicaments pour le traitement des caries, des aphtes, des périodontites
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p.ex. arthrites, arthroses
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

The present invention relates to a composition including a colored rice extract as an active ingredient for the prevention, reduction, or treatment of skin wrinkles. Specifically, the colored rice extract of the present invention, which is derived from a mutant rice plant (KCTC 18500P) capable of producing seeds with a yellow bran layer, has the effect of reducing the expression of MMP-9 (matrix metalloproteinase-9) and thus can be utilized in cosmetics, health functional foods, or pharmaceuticals for the prevention, reduction, or treatment of skin wrinkles.

Classes IPC  ?

• A61K 8/9794 - Liliopsida [monocotylédones]
• A61Q 19/08 - Préparations contre le vieillissement
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/899 - Poaceae ou Gramineae (famille des céréales), p.ex. bambou, blé ou canne à sucre
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

The present invention relates to a composition for preventing, ameliorating, or treating obesity, comprising colored rice extract as an active ingredient. Specifically, as the colored rice extract of the present invention obtained from a mutant rice plant (KCTC 18500P) capable of producing seeds with a yellow seed coat, has the effect of inhibiting fat accumulation in the 3T3-L1 cell line and suppressing the expression of obesity-related genes (PPARγ, and FASN), the colored rice extract may be very effectively used in functional health foods or pharmaceuticals for preventing, ameliorating, or treating obesity.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A01H 6/46 - Gramineae ou Poaceae, p.ex. ivraie, riz, blé ou maïs
• A61K 36/899 - Poaceae ou Gramineae (famille des céréales), p.ex. bambou, blé ou canne à sucre
• A61P 3/04 - Anorexigènes; Médicaments de l'obésité
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

The present invention relates to a composition for preventing, ameliorating, or treating Alzheimer's disease, comprising, as active ingredients, a Vitis vinifera stem extract and a compound isolated therefrom. The active ingredient of the present invention, the Vitis vinifera stem extract or vitisin A, may inhibit infection caused by herpes simplex virus and have an excellent inhibitory effect on Alzheimer's disease triggers in the brain tissue of an animal model infected with herpes simplex virus, and thus the composition of the present invention can be useful as a therapeutic agent for Alzheimer's disease, a health functional food or feed additive for preventing or ameliorating Alzheimer's disease.

Classes IPC  ?

• A61K 36/87 - Vitaceae ou Ampelidaceae (famille de la vigne ou du raisin), p.ex. raisin, vitis rotumdifolia ou vigne vierge
• A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide condensés avec un carbocycle, p.ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A23L 33/10 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons
• A23K 20/121 - Composés hétérocycliques contenant de l’oxygène ou du soufre comme hétéroatome

Abrégé

The present invention pertains to: an antiviral composition against coronavirus, containing a maple leaf extract as an active ingredient; a method for preventing or treating coronavirus infection diseases, the method comprising the step of administering a composition containing a maple leaf extract as an active ingredient to an individual who shows symptoms of coronavirus infection or is at risk of developing such symptoms; and a use of a composition containing a maple leaf extract as an active ingredient for antiviral activity against coronavirus. The present invention can be utilized in the development of antiviral agents for preventing or treating coronavirus diseases.

Classes IPC  ?

• A61K 36/20 - Aceraceae (famille de l'érable)
• A61K 36/538 - Schizonepeta
• A61K 36/185 - Magnoliopsida (dicotylédones)
• A61K 36/14 - Cupressaceae (famille du cyprès), p.ex. genévrier ou cyprès
• A61K 36/296 - Epimedium
• A61K 36/72 - Rhamnaceae (famille de la bourdaine), p.ex. bourdaine, jujubier ou schefflera
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

A cognitive training method based on eye tracking according to the present invention may comprise the steps of: providing content including a target stimulus and a distractor stimulus to a virtual space of each of a plurality of participants; monitoring the eye of each of the plurality of participants with respect to the target stimulus and the distractor stimulus on the basis of an eye tracking method; on the basis of a result of the monitoring, calculating a concentration level for the content for each of the plurality of participants; and providing a graphic object classified for each of the plurality of participants to a virtual space of an instructor, and providing information on the concentration level of each of the plurality of participants to the graphic object.

Classes IPC  ?

• A61B 5/16 - Dispositifs pour la psychotechnie; Test des temps de réaction
• G09B 5/12 - Matériel à but éducatif à commande électrique avec présentation individuelle d'une information à une pluralité de postes d'élèves différents postes étant capables de présenter des informations différentes simultanément

Abrégé

The present invention relates to a composition for the prevention, amelioration or treatment of an anterior segment eye disease, the composition comprising a plant extract of the genus Aloe as an active ingredient. When the Aloe vera extract of the present invention is orally administered to a dry eye-induced animal model, there are the effects of increasing tear volume and reducing corneal distortion and corneal smoothness score, and thus, the Aloe vera extract can be effectively used in health functional foods or medicines for anterior segment eye diseases.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23L 3/44 - Lyophilisation
• A23L 29/00 - Aliments ou produits alimentaires contenant des additifs; Leur préparation ou leur traitement
• A61K 36/886 - Aloeaceae (famille de l'aloès), p.ex. aloe vera
• A61P 27/02 - Agents ophtalmiques
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

The present invention relates to a composition for the prevention, amelioration or treatment of fatty liver disease, containing a Glycine max extract as an active ingredient. The Glycine max extract of the present invention, particularly a Glycine max extract having a genetic resource name of Shinpaldalkong ( IT No.: IT343931) or KLG 16001 (IT No.: IT238318) has the effects of suppressing fatty liver formation and reducing blood ALT and AST contents that are increased by a high-sucrose diet, in a high-sucrose diet animal model, and thus can be effectively used as a therapeutic agent for fatty liver disease or an ingredient of a health functional food for ameliorating fatty liver.

Classes IPC  ?

• A61K 36/48 - Fabaceae ou Leguminosae (famille du pois ou des légumineuses); Caesalpiniaceae; Mimosaceae; Papilionaceae
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

A composition for strengthening, developing, differentiating, or regenerating muscle, or preventing, ameliorating, or treating muscle loss or muscle fatigue includes a Schizonepeta tenuifolia extract as an effective component. The Schizonepeta tenuifolia extract as an effective component has the effects of restoring the viability of muscle cells, increasing the endurance time on the rotarod performance test, i.e., the holding time without falling off from the rod, compared to the control group, reducing the content of LDH, AST, and ALT in blood, increasing the grip strength, enhancing the expression amount of energy metabolism-related genes in muscle tissues, increasing the density of muscle fibers in muscle tissues, inducing a change in the fibroblast arrangement to have a well-organized structure, and reducing the expression of MuRF1 in muscle tissues, as compared to the control group.

Classes IPC  ?

• A61K 36/538 - Schizonepeta
• A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire

Abrégé

The present invention relates to a composition for prevention, alleviation, or treatment of bone disease, containing salvianolic acid as an active ingredient, the salvianolic acid of the present invention, specifically, salvianolic acid A or methyl salvionolate A having an excellent effect of promoting osteoblast differentiation, methyl salvionolate A having an excellent effect of inhibiting osteoclast differentiation, and salvianolic acid A, when administered in an ovariectomized mouse, having an excellent effect of inhibiting bone loss, and thus the composition of the present invention, containing salvianolic acid A or methyl salvionolate A as an active ingredient may be usefully employed as an agent for prevention, alleviation, or treatment of bone disease.

Classes IPC  ?

• A61K 31/216 - Esters, p.ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p.ex. bénactizyne, clofibrate
• A61P 19/00 - Médicaments pour le traitement des troubles du squelette
• A23L 33/10 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs
• A23K 20/111 - Composés aromatiques

Abrégé

A composition for preventing, ameliorating or treating an androgen-dependent disorder includes Phyllostachys pubescens extract as an effective component. It was found that, compared to the extracts of other types of bamboo, the Phyllostachys pubescens extract of the present invention can significantly reduce the expression amount of the SRD5A2 gene which encodes 5α-reductase while hardly showing any cytotoxicity. The composition of the present invention was found to have effects that can reduce the prostate weight, reduce the proliferation of epithelial cells in prostate tissues, and also can reduce the content of testosterone, dihydrotestosterone, PSA, and SRD5A2 in blood serum. Thus, the composition of the present invention can be advantageously used for an androgen-dependent disorder.

Classes IPC  ?

• A61K 36/899 - Poaceae ou Gramineae (famille des céréales), p.ex. bambou, blé ou canne à sucre
• A61P 5/26 - Androgènes
• A61K 8/9794 - Liliopsida [monocotylédones]

Abrégé

The present invention relates to a composition for the prevention, amelioration or treatment of rhinitis, the composition comprising a Gardenia jasminoides extract from which a pigment is removed, as an active ingredient. The Gardenia jasminoides extract, from which a pigment is removed, showed a reduced number of sneezes and a reduced number of nose rubbings in a rhinitis-induced animal model, and has the effect of reducing inflammation in nasal tissue, and thus can be used as a health functional food, medicine or quasi-drug for the prevention, amelioration or treatment of rhinitis.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23L 5/20 - Préparation ou traitement des aliments ou produits alimentaires en général; Aliments ou produits alimentaires ainsi obtenus; Leurs matériaux Élimination de constituants indésirables, p.ex. désodorisation ou détoxication
• A61K 36/744 - Gardenia
• A61P 11/02 - Agents rhinologiques, p.ex. décongestionnants

Abrégé

The present invention relates to a composition for promoting memory and preventing, alleviating or treating cognitive impairment, containing Yuk-Gunja-Tang as an active ingredient. Specifically, Yuk-Gunja-Tang, which is prepared by putting a mixture of Panax ginseng, Atractylodis Rhizoma Alba, Poria cocos, Glycyrrhizae Radix et Rhizoma, Citri Unshius Pericarpium, Pinellia ternata, Zingiberis Rhizoma Recens and Zizyphi Fructus in water and boiling same, has neuroprotective effects superior to those of individual extracts of each of Panax ginseng, Atractylodis rhizoma alba, Poria cocos, Glycyrrhizae Radix et Rhizoma, Citri Unshius Pericarpium, Pinellia ternata, Zingiberis Rhizoma Recens and Zizyphi Fructus, and exhibits effects of improving memory and cognitive function when administered to an animal model with scopolamine-induced cognitive decline, and thus can be effectively used as a food, a drug and the like for prevention or treatment of brain diseases including Alzheimer's disease, Parkinson's disease, mild cognitive impairment and the like.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons
• A61K 36/258 - Panax (ginseng)
• A61K 36/284 - Atractylodes
• A61K 36/076 - Poria
• A61K 36/484 - Glycyrrhiza (réglisse)
• A61K 36/752 - Citrus, p.ex. citron vert, orange ou citron
• A61K 36/8888 - Pinellia
• A61K 36/9068 - Zingiber, p.ex. gingembre
• A61K 36/725 - Ziziphus, p.ex. jujube

Abrégé

The present invention relates to a composition for prevention, amelioration or treatment of a coronavirus infection, comprising a Sorbus commixta extract as an active ingredient. The Sorbus commixta extract has the effect of protecting cells from a coronavirus infection and has an excellent effect of inhibiting viral replication in cells and viral infection in cells, and thus the composition of the present invention, comprising the Sorbus commixta extract as an active ingredient may be usefully employed as a coronavirus infection therapeutic agent, an anti-coronavirus health functional food, quasi-drug, cosmetic or feed additive.

Classes IPC  ?

• A61K 36/73 - Rosaceae (famille de la rose), p.ex. fraise, aronia, mûre ou pyracantha
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 8/9789 - Magnoliopsida [dicotylédones]
• A61Q 19/00 - Préparations pour les soins de la peau
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

The present invention relates to a composition for the prevention, amelioration or treatment of coronavirus infection, the composition comprising a Siegesbeckia pubescens extract as an active ingredient. The Siegesbeckia pubescens extract has the effect of protecting cells from coronavirus infection, and has an excellent effect of suppressing viral replication in cells and viral infection in cells, and thus, the composition comprising the Siegesbeckia pubescens extract as an active ingredient according to the present invention can be effectively used as a therapeutic agent for coronavirus infection or as an anti-coronavirus health functional food, quasi-drug, cosmetic, or feed additive.

Classes IPC  ?

• A61K 36/28 - Asteraceae ou Compositae (famille de l'aster ou du tournesol), p.ex. camomille, chrysanthème matricaire, achillée ou echinacée
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 8/9789 - Magnoliopsida [dicotylédones]
• A61Q 19/00 - Préparations pour les soins de la peau
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

The present invention relates to a composition including a Daihong Crataegus pinnatifida Bunge extract as an active ingredient for improving gut health or treating inflammatory bowel disease. The Daihong Crataegus pinnatifida Bunge extract is almost free of cytotoxicity, exhibits protective activity for the intestines, reduces the expression levels of necroptosis markers, and has the effect of restoring the length of the intestines in animal models with induced inflammatory bowel disease. Therefore, the extract can be beneficially used in health functional foods or pharmaceuticals for intestinal health.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/734 - Crataegus (aubépine)
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons
• A23P 10/00 - Mise en forme ou traitement des produits alimentaires caractérisés par les produits

Abrégé

22, and LTB4) and cartilage degeneration-inducing factors (MMP-2 and MMP). Therefore, the composition of the present invention can be effectively used for preventing, ameliorating, or treating arthritis and joint pain.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/185 - Magnoliopsida (dicotylédones)
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p.ex. arthrites, arthroses
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

The present invention relates to a composition for the prevention, amelioration or treatment of allergic respiratory diseases comprising an Alpinia officinarum Hance extract as an active ingredient. Specifically, as an Alpinia officinarum Hance extract has excellent effects of reducing airway hyperresponsiveness, inhibiting the infiltration of immune cells such as eosinophils and neutrophils increased by asthma induction in a nasal lavage fluid, reducing IgE content in serum, and selectively inhibiting the Th2 immune response, the Alpinia officinarum Hance extract can be effectively used in functional health foods, medicines, etc. for allergic respiratory diseases.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/9062 - Alpinia, p.ex. Alipinia purpurata ou grand galanga
• A61P 37/08 - Agents antiallergiques
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

The present invention relates to a composition for preventing, ameliorating, or treating coronavirus infections, the composition comprising Euljatang extract as an active ingredient. The Euljatang extract has excellent effects of protecting cells from coronavirus infections, inhibiting the proliferation of viruses, and reducing the lethality of infections in animal models infected with coronaviruses, and thus the composition according to the present invention comprising the Euljatang extract as an active ingredient can be effectively used as a therapeutic agent for coronavirus infections, health functional food for anti-coronavirus, a quasi-drug, a cosmetic, or a feed additive.

Classes IPC  ?

• A61K 36/232 - Angelica
• A61K 36/233 - Bupleurum
• A61K 36/53 - Lamiaceae ou Labiatae (famille de la menthe), p.ex. thym, romarin ou lavande
• A61K 36/484 - Glycyrrhiza (réglisse)
• A61K 36/71 - Ranunculaceae (famille du bouton d'or), p.ex. pied d'alouette, hépatique, hydrastis, ancolie
• A61K 36/70 - Polygonaceae (famille du sarrasin), p.ex. chorizanthe pungens ou patience
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 8/9789 - Magnoliopsida [dicotylédones]
• A61Q 19/00 - Préparations pour les soins de la peau

Abrégé

The present invention relates to a composition for preventing, alleviating or treating coronavirus infection, containing a Gwakhyanggunggi-san extract as an active ingredient. The Gwakhyangjeonggi-san extract has the excellent effects of protecting cells from coronavirus infection, inhibiting the proliferation of viruses and reducing the mortality rate caused by infection in animal models infected with coronavirus, and thus the composition of the present invention, comprising the Gwakhyangjeonggi-san extract as an active ingredient, can be effectively used as an agent for treating coronavirus infection, an anti-coronavirus health functional food, quasi-drug, cosmetic product, or feed additive.

Classes IPC  ?

• A61K 36/532 - Agastache, p.ex. hysope
• A61K 36/535 - Perilla (Perilla nankinensis)
• A61K 36/232 - Angelica
• A61K 36/889 - Arecaceae, Palmae ou Palmaceae (famille du palmier), p.ex. dattier ou cocotier ou palmier nain
• A61K 36/076 - Poria
• A61K 36/54 - Lauraceae (famille du laurier), p.ex. cannelle ou sassafras
• A61K 36/284 - Atractylodes
• A61K 36/752 - Citrus, p.ex. citron vert, orange ou citron
• A61K 36/8888 - Pinellia
• A61K 36/346 - Platycodon

Abrégé

The present invention relates to a composition for preventing, ameliorating, or treating atopic dermatitis comprising an extract of Alpinia officinarum Hance as an active ingredient. Specifically, as an extract of Alpinia officinarum Hance suppresses an increase in ear thickness in an animal model with atopic dermatitis, ameliorates skin lesions such as skin damage and the like, and has an excellent effect in reducing the secretion of chemokine and immunoglobulin E, the extract of Alpinia officinarum Hance can be effectively used in functional health foods, pharmaceutical products, etc. for atopic dermatitis.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/9062 - Alpinia, p.ex. Alipinia purpurata ou grand galanga
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

The present invention relates to a method for segmenting the abdomen for abdominal measurement and stimulation. Designed to uniformly divide the abdomen on the basis of location, the method allows for diagnostic and therapeutic actions to be taken in each segment and thus assists acupuncturists and medical professionals in abdominal diagnosis.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
• A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p.ex. pour le traitement de la luxation ou pour la protection de bords de blessures

Abrégé

The present invention relates to: an antiviral pharmaceutical composition containing a maple extract as an active ingredient; a pharmaceutical composition, containing a maple extract as an active ingredient, for preventing or treating influenza virus infectious diseases; a method for preventing or treating influenza virus infectious diseases, the method comprising a step for administering a composition containing a maple extract as an active ingredient to an individual who shows or is likely to show symptoms of influenza virus infectious diseases; and an antiviral use of the composition containing a maple extract as an active ingredient. A maple leaf extract exhibits the effect of inhibiting influenza virus infection, and thus can be used for developing an antiviral agent for preventing or treating influenza virus infectious diseases.

Classes IPC  ?

• A61K 36/20 - Aceraceae (famille de l'érable)
• A61P 31/12 - Antiviraux
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

The present invention relates to a composition for the prevention, amelioration or treatment of coronavirus infection, comprising a Melia toosendan fructus extract as an active ingredient. The Melia toosendan fructus extract has the effect of protecting cells from coronavirus infection, and has an excellent effect of suppressing viral replication in cells and viral infection in cells, and thus, the composition of the present invention, comprising the Melia toosendan fructus extract as an active ingredient, can be effectively used as a therapeutic agent for coronavirus infection or a health functional food, quasi-drug, cosmetic or feed additive for anti-coronavirus.

Classes IPC  ?

• A61K 36/58 - Meliaceae (famille du margousier ou de l'acajou), p.ex. margosa (neem)
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 8/9789 - Magnoliopsida [dicotylédones]
• A61Q 19/00 - Préparations pour les soins de la peau
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

The present invention relates to a composition for the prevention, amelioration or treatment of asthma, containing a Malus baccata var. mandshurica extract as an active ingredient. The Malus baccata var. mandshurica extract, which is an active ingredient of the present invention, has the effects of reducing the number of inflammatory cells in an asthma animal model, reducing IgE content in the bronchoalveolar lavage fluid (BALF) and plasma of an asthma animal model, reducing IL-13 content in the BALF of an asthma animal model, reducing the hyperplasia of mucus-secreting cells due to infiltration of inflammatory cells into lung tissue or bronchial remodeling and the amount of mucus, and reducing the activity of β-hexosaminidase in mast cells with induced degranulation, and thus can be effectively used as a therapeutic agent for asthma and a material of a health functional food for ameliorating asthma.

Classes IPC  ?

• A61K 36/73 - Rosaceae (famille de la rose), p.ex. fraise, aronia, mûre ou pyracantha
• A61P 11/06 - Antiasthmatiques
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

The present invention relates to a composition for hangover relief, the composition comprising a Cucumis melo L. extract as an active ingredient. Specifically, the Cucumis melo L. extract can mitigate an increase in blood ethanol concentration caused by alcohol consumption and effectively increase the activity of ADH and ALDH in the blood. Thus, the composition according to the present invention can be effectively used as a health-functional food, drug, or quasi-drug for hangover relief.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23P 10/20 - Agglomération; Granulation; Mise en comprimés
• A23P 10/28 - Mise en comprimés; Fabrication de produits alimentaires en barres par compression d’un mélange pulvérulent sec
• A23P 10/30 - Mise en capsules de particules, p.ex. additifs alimentaires
• A23L 2/38 - Autres boissons non alcoolisées
• A61K 36/42 - Cucurbitaceae (famille du concombre)
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif

Abrégé

The present invention relates to a screening composition for a therapeutic agent for coronavirus infection, comprising a CoV RdRp expression vector and a bicistronic reporter vector, a screening kit for a therapeutic agent for coronavirus infection, comprising the composition, and a method for screening a therapeutic agent for coronavirus infection using the composition or kit. When the screening composition for a therapeutic agent for coronavirus infection, provided by the present invention, is used, candidate materials that can have direct influences on the activity of CoV RdRp can be screened more quickly and easily, and thus, the composition can be widely used in the development of therapeutic agents for coronavirus infection.

Classes IPC  ?

• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN

Abrégé

The present invention relates to a composition which is for preventing, ameliorating, or treating metabolic diseases, and contains an extract of Lysimachia mauritiana as an active ingredient. The extract of Lysimachia mauritiana not only reduces body weight, weight gain, food efficiency ratio, body fat, fat cell size, liver weight, liver fat accumulation, blood triglycerides, total cholesterol, and LDL cholesterol and improves GPT, but also has the effect of inhibiting adipocyte differentiation and fat accumulation in 3T3-L1 adipocytes, and thus can be effectively used as a health functional food or medicine for preventing, ameliorating, or treating metabolic diseases including obesity, dyslipidemia, and fatty liver.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons
• A61K 36/185 - Magnoliopsida (dicotylédones)
• A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
• A61P 3/04 - Anorexigènes; Médicaments de l'obésité
• A61P 3/06 - Antihyperlipémiants
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques

Abrégé

The present invention relates to novel asaroidoxazine C and an anti-cancer use thereof. More specifically, provided are: asaroidoxazine C represented by Formula 1 below, an isomer thereof, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition and a functional health food composition using same; a method for preventing, ameliorating, or treating a cancer using same; and a method for isolating the asaroidoxazine C.

Classes IPC  ?

• C07D 498/04 - Systèmes condensés en ortho
• A61K 31/5365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p.ex. 1,2-oxazines condensées en ortho ou en péri avec des systèmes hétérocycliques
• A61K 36/268 - Asarum (cabaret sauvage)
• A61P 35/00 - Agents anticancéreux
• A23L 33/10 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs

Abrégé

The present invention relates to an anticancer use of aristoloxazine C and, more specifically, to a pharmaceutical composition and a health functional food composition which use aristoloxazine C represented by chemical formula 1 or an isomer or pharmaceutically acceptable salt thereof, a method for preventing, ameliorating, or treating cancer by using same, and a method for isolating aristoloxazine C.

Classes IPC  ?

• A61K 31/5365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p.ex. 1,2-oxazines condensées en ortho ou en péri avec des systèmes hétérocycliques
• A61K 36/268 - Asarum (cabaret sauvage)
• A61P 35/00 - Agents anticancéreux
• A23L 33/10 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs
• C07D 498/04 - Systèmes condensés en ortho

Abrégé

The present invention relates to a use of Asaroidoxazine B having anticancer activity and, more specifically, to: a pharmaceutical composition and a health functional food composition, each utilizing Asaroidoxazine B represented by chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt thereof; a method for preventing, alleviating, or treating cancer, using same; and a method for isolation of the Asaroidoxazine B.

Classes IPC  ?

• A61K 31/5365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p.ex. 1,2-oxazines condensées en ortho ou en péri avec des systèmes hétérocycliques
• A61K 36/268 - Asarum (cabaret sauvage)
• A61P 35/00 - Agents anticancéreux
• A23L 33/10 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs
• C07D 498/04 - Systèmes condensés en ortho

Abrégé

The present invention relates to a composition for the prevention, amelioration or treatment of a respiratory disease, containing a Lysimachia mauritiana extract as an active ingredient. The Lysimachia mauritiana extract has the effect of reducing the amount of production of chemokine RANTES, which is a pro-inflammatory mediator, from bronchial epithelial cells, which are respiratory cells, and thus can be effectively used as a health functional food or medicine for a respiratory disease, including asthma or chronic obstructive pulmonary disease (COPD).

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/185 - Magnoliopsida (dicotylédones)
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

The present invention relates to a composition comprising a Cardamine flexuosa extract as an active ingredient for prevention, alleviation, or treatment of respiratory disease. The Cardamine flexuosa extract has the effect of reducing the production of chemokine RANTEST, which is an inflammation-inducing mediator, from bronchial epithelial cells, which are respiratory cells, and thus can be advantageously used as a health functional food, a medical product, or a feed additive against respiratory diseases including asthma or chronic obstructive pulmonary disease (COPD).

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/31 - Brassicaceae ou Cruciferae (famille de la moutarde), p.ex. broccoli, chou ou chou-rave
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

The present invention relates to a use of an Apios americana tuber extract for protection against alcoholic liver damage or alcoholic brain damage, and more particularly, provides a composition for protection against alcoholic liver damage or alcoholic brain damage and a method for protection against alcoholic liver damage or alcoholic brain damage, each using an Apios americana tuber extract. In addition, the present invention provides a composition for the prevention, alleviation, or treatment of alcoholic liver disease or brain nervous system disease and a method for the prevention, alleviation, or treatment of alcoholic liver disease or brain nervous system disease, each using an Apios americana tuber extract. Furthermore, the present invention provides a composition for relieving hangover and a method for relieving hangover, each using an Apios americana tuber extract.

Classes IPC  ?

• A61K 36/48 - Fabaceae ou Leguminosae (famille du pois ou des légumineuses); Caesalpiniaceae; Mimosaceae; Papilionaceae
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

The present invention relates to a 2-aminoquinazoline derivative or a pharmaceutically acceptable salt thereof and, more specifically, to a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof, and an anti-viral pharmaceutical composition comprising same as an active ingredient. [chemical formula 1]

Classes IPC  ?

• C07D 239/95 - Quinazolines; Quinazolines hydrogénées avec des hétéro-atomes liés directement en positions 2 et 4
• C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07F 9/06 - Composés du phosphore sans liaisons P—C
• C07F 9/11 - Esters des acides phosphoriques avec des composés hydroxyalkylés sans substituant supplémentaire sur l'alkyle
• A61K 31/517 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. quinazoline, périmidine
• A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
• A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p.ex. fosfosal, dichlorvos, malathion
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present invention relates to use of a composition comprising Banhasasim-tang as an active ingredient for the treatment, amelioration or prevention of Alzheimer's disease caused by ApoE4 genetic variation. The composition comprising Banhasasim-tang as an active ingredient and a treatment method, according to the present invention, exhibit excellent effects of reducing amyloid beta protein and inhibiting the precipitation thereof in a manner specific to Alzheimer's disease caused by ApoE4 genetic variation, and thus are greatly used as a preventive, ameliorating or therapeutic composition specific to Alzheimer's disease caused by ApoE4 genetic variation.

Classes IPC  ?

• A61K 36/8888 - Pinellia
• A61K 36/725 - Ziziphus, p.ex. jujube
• A61K 36/484 - Glycyrrhiza (réglisse)
• A61K 36/258 - Panax (ginseng)
• A61K 36/9068 - Zingiber, p.ex. gingembre
• A61K 36/53 - Lamiaceae ou Labiatae (famille de la menthe), p.ex. thym, romarin ou lavande
• A61K 36/718 - Coptis (Coptis chinensis)
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

The present invention has confirmed that Castanea crenata Sieb reduces the expression of an influenza A virus protein, the expression of inflammatory cytokines increased by infection therewith, and the activity of NF-kB, remarkably reduces the mortality of an animal model infected with influenza A virus, suppresses weight loss caused by viral infection, and has the effect of inducing the expression of innate immunity-related factors and the phosphorylation of factors involved in the activation of immune-related signaling pathways. Therefore, Castanea crenata Sieb can have various useful applications for the prevention, alleviation or treatment of diseases caused by influenza A virus, and can have various useful applications for enhancing immune function.

Classes IPC  ?

• A61K 36/49 - Fagaceae (famille du hêtre), p.ex. chêne ou châtaignier
• A61K 35/644 - Cire d’abeille; Propolis; Gelée royale; Miel
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23L 33/125 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons
• A23K 10/20 - Produits alimentaires pour animaux à base de matières d’origine animale
• A23L 33/10 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs

Abrégé

The present invention relates to a composition comprising a Rubus coreanus extract as an active ingredient for inhibiting tumor growth. The Rubus coreanus extract was identified to: bind to PD-L1 located on the surface of cancer cells to interfere with the interaction of cancer cells with PD-1 located on the surface of T cells and activate T cells, thereby exhibiting an inhibitory effect on tumor growth; have excellent anti-tumor immune efficacy in a humanized PD-1 animal model which expressed human PD-L1 and had MC38 colon cancer induced therein; and exhibit a synergistic effect when administered in combination with an anticancer agent.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/73 - Rosaceae (famille de la rose), p.ex. fraise, aronia, mûre ou pyracantha
• A61P 35/00 - Agents anticancéreux
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
• A23L 19/00 - Produits à base de fruits ou de légumes; Leur préparation ou leur traitement

Abrégé

The present invention relates to a composition for the prevention, amelioration or treatment of muscle diseases, comprising ginsenoside Rc. Ginsenoside Rc inhibits myoblast apoptosis under oxidative stress, increases the activity of PGC1-α, which is a metabolic regulator and a mitochondrial biogenesis factor, in myoblasts and myotubes, inhibits a reduction in PGC1-α and MyH in myotubes, maintains mitochondrial mass, and suppresses muscle damage caused by oxidative stress by inhibiting an increase in MuRF and MAFbx, which are proteins involved in muscle cell breakdown, and thus can be used for the prevention, amelioration or treatment of muscle diseases, in particular, muscle diseases caused by decreased muscular function, muscle wasting, or muscular degeneration.

Classes IPC  ?

• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine liés à un système carbocyclique condensé, p.ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
• A23L 33/125 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon

Abrégé

A method and a device for improving deep learning performance for similar image classification are disclosed. A method for improving deep learning performance for similar image classification, according to one embodiment of the present invention, may comprise the steps of: creating a confusion matrix (CM) by using a correct answer value of label data and a prediction value of a model, generated during learning by means of a deep learning model with respect to an input image; defining, from the CM, a confusion rate (CR), which is the rate with respect to the difference between a class according to the prediction value and a class according to the correct answer value; and weighting the CR against a prescribed loss function so as to correct the learning process by means of the deep learning model.

Classes IPC  ?

• G06N 3/08 - Méthodes d'apprentissage
• G06N 3/04 - Architecture, p.ex. topologie d'interconnexion
• G06K 9/62 - Méthodes ou dispositions pour la reconnaissance utilisant des moyens électroniques

Abrégé

The present invention relates to a composition for preventing, alleviating, or treating respiratory diseases, comprising fermented centella asiatica extract as an active ingredient. The active ingredient of the present invention reduces the production of RANTES, which is an inflammatory chemokine, in bronchial epithelial cells, which are respiratory cells, has an effect of protecting cells damaged by LPS induction, and has an effect of reducing an expression level of inflammatory cytokine IL-6. In addition, the active ingredient can reduce the number of neutrophils and regulate the expression level of inflammatory cytokines or chemokines in lung injury animal models. As such, the active ingredient can be effectively used as: a health functional food for preventing or alleviating respiratory diseases; and a medicine for preventing or treating respiratory diseases.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23L 33/135 - Bactéries ou leurs dérivés, p.ex. probiotiques
• A23L 33/14 - Levures ou leurs dérivés
• A23L 3/00 - Conservation des aliments ou produits alimentaires, en général, p.ex. pasteurisation ou stérilisation, spécialement adaptée aux aliments ou produits alimentaires
• A61K 36/23 - Apiaceae ou Umbelliferae (famille de la carotte), p.ex. aneth, cerfeuil, coriandre ou cumin
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

Provided are a vaccine adjuvant composition including, as an active ingredient, bavachin capable of improving antibody titer and enhancing cellular immunity and humoral immunity when administered together with an antigen, a vaccine preparation including the bavachin and an antigen, a method of promoting an immune response, the method including the step of administering the vaccine adjuvant composition to a subject together with a vaccine composition or before and after administration of the vaccine composition, and a vaccine adjuvant composition for promoting an immune response, the vaccine adjuvant composition including the bavachin. Since the vaccine adjuvant composition of the present invention includes bavachin isolated from an extract of Psoralea corylifolia, of which safety has been secured, it may exhibit safety and may enhance both the humoral and cellular immune responses as well as the titer of antibodies generated by antigens.

Classes IPC  ?

• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
• A61P 37/04 - Immunostimulants

Abrégé

A composition according to an embodiment of the present disclosure can be used for inhibiting tumor proliferation and includes a Salvia plebeia extract as an effective component. It was found that, as a result of binding to PD-L1 present on a surface of cancer cell, Salvia plebeia extract blocks the interaction between cancer cell and PD-1 present on a surface of immune T cell to activate T cells and exhibit an inhibitory effect on tumor proliferation. It was also found that, according to co-culture of cells of colon cancer, breast cancer, or lung cancer with T cells, the group treated with Salvia plebeia extract shows higher effect of causing cancer cell death.

Classes IPC  ?

• A61K 36/537 - Salvia (sauge)
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur 
• A61P 35/00 - Agents anticancéreux

Abrégé

The objective of the present invention is to provide an apparatus and method for evaluating meridian muscle activity, wherein the activity of each of a plurality of meridian muscle groups is evaluated using measurement data measured using a sensor and a simulation model. More specifically, the present invention comprises: a measurement unit for measuring the gait of a user; a calculation unit for calculating lower extremity joint torque values of the user using measurement results of the measurement unit; and an evaluation unit for evaluating the activity for each of the meridian muscles of the lower extremities of the user on the basis of the lower extremity joint torque values. According to the invention, a user's asymmetrical gait can be detected using only an apparatus having a simple structure.

Classes IPC  ?

• A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p.ex. tremblement de la tête ou des mains ou mobilité d'un membre
• A61B 5/103 - Dispositifs de mesure pour le contrôle de la forme, du dessin, de la dimension ou du mouvement du corps ou de parties de celui-ci, à des fins de diagnostic
• A61B 5/397 - Analyse des électromyogrammes
• A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus

Abrégé

The present invention relates to a composition for inhibiting tumor growth, containing an extract of Sanguisorba officinalis as an active ingredient. It has been identified that a Sanguisorba officinalis extract binds to PD-L1 on cancer cell surfaces to block the interaction of cancer cells with PD-1 on the surface of T cells, and thus activates T cells to exhibit the effect of inhibiting tumor growth, and the present invention can reduce the size and weight of a tumor by being administered to an animal model in which colon cancer has been induced, and can increase immune cells (CD8 T cells) and granzyme B secretion in cancer tissues.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/739 - Sanguisorba (pimprenelle)
• A61K 31/538 - 1,4-Oxazines, p.ex. morpholine condensées en ortho ou en péri avec des systèmes carbocycliques
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur 
• A61P 35/00 - Agents anticancéreux
• A61P 31/00 - Agents anti-infectieux, c. à d. antibiotiques, antiseptiques, chimiothérapeutiques
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

Lysimachiae HerbaRaphani SemenBuddlejae FlosBuddlejae Flos extract. The Lysimachiae Herba, Raphani Semen or Buddlejae Flos extract according to the present invention has the effect of fundamentally alleviating the symptoms of cancer cachexia by suppressing the loss of body weight, muscle and fat, caused by tumors, not due to an increase in feed intake through increased appetite, and is safe and has no side effects, and thus can be used for the prevention, amelioration or treatment of cachexia.

Classes IPC  ?

• A61K 36/56 - Loganiaceae (famille de la logania), p.ex. jasmin de Virginie
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• A61P 35/00 - Agents anticancéreux
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/31 - Brassicaceae ou Cruciferae (famille de la moutarde), p.ex. broccoli, chou ou chou-rave
• A61K 36/53 - Lamiaceae ou Labiatae (famille de la menthe), p.ex. thym, romarin ou lavande

Abrégé

The Agastache rugosa extract or the isoagastachoside or crude polysaccharide fraction included in the extract according to the present invention can be prepared based on plants being domestically cultivated, and thus is advantageous in terms of time and cost, and can effectively inhibit the differentiation, growth, and bone resorption functions of osteoclast progenitor cells, thus increasing bone density and the like, and accordingly, can be effectively used for the prevention, amelioration, or treatment of diseases related to bone loss caused by differentiation into osteoclasts or excessive activity of osteoclasts. In addition, the active ingredient, which is a plant-derived natural substance, is safe due to fewer side effects on the human body compared to chemical drugs, and inhibits osteoclast progenitor cells independently of estrogen, and thus can be widely used in osteoporosis occurring due to various causes other than menopause.

Classes IPC  ?

• A61K 36/532 - Agastache, p.ex. hysope
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61P 19/08 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p.ex. rachitisme, maladie de Paget

Abrégé

The present invention relates to a composition for preventing, ameliorating, or treating muscle strengthening, muscle building, muscle differentiation, muscle regeneration, muscle loss, or muscle fatigue, comprising a Schizonepeta tenuifolia extract as an active ingredient. The Schizonepeta tenuifolia extract which is the active ingredient of the present invention has the effects of recovering cell viability of muscle cells, increasing the holding time without detachment from a rod as compared with a control group when a rotarod test is performed, and reducing amounts of LDH, AST, and ALT in the blood. In addition, the Schizonepeta tenuifolia extract has the effects of increasing grasping strength, increasing an expression level of an energy metabolism-related gene in muscle tissue, increasing the density of muscle fibers in muscle tissue, changing a fibroblast arrangement in an orderly manner, and reducing the expression of MuRF1.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/538 - Schizonepeta
• A61K 36/884 - Alismataceae (famille du fluteau)
• A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire

Abrégé

The present invention relates to an anti-coronavirus use of an antiviral composition containing a Ramulus-mori-derived compound as an active ingredient. Specifically, a Ramulus-mori-derived compound of the present invention exhibits an inhibitory effect on an infection caused by coronavirus such as SARS-coronavirus-2 (SARS-CoV-2), and thus relates to the development of an antiviral agent for preventing or treating viral diseases.

Classes IPC  ?

• A61K 36/605 - Morus (mûre)
• A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p.ex. cannabinols, méthanthéline
• A61K 31/353 - 3,4-Dihydrobenzopyranes, p.ex. chromane, catéchine
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons
• A23K 20/121 - Composés hétérocycliques contenant de l’oxygène ou du soufre comme hétéroatome

Abrégé

The present invention relates to an anti-coronavirus use of an antiviral composition containing a Geranium herb extract as an active ingredient. Specifically, the present invention relates to the development of an antiviral agent for preventing or treating viral diseases since a Geranium herb extract of the present invention exhibits an inhibitory effect on an infection caused by coronavirus such as SARS-coronavirus-2 (SARS-CoV-2).

Classes IPC  ?

• A61K 36/185 - Magnoliopsida (dicotylédones)
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

The present invention relates to a composition for preventing, alleviating, or treating allergic diseases, comprising an extract of Spatholobus suberectus as an active ingredient. The extract of Spatholobus suberectus of the present invention has an effect of reducing the secretion amount of chemokines (MDC and RANTES) and the formation amount of cytokines (IL-4), and thus may be advantageously utilized in functional health food or drugs for preventing, alleviating, or treating allergic diseases.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/48 - Fabaceae ou Leguminosae (famille du pois ou des légumineuses); Caesalpiniaceae; Mimosaceae; Papilionaceae
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 37/08 - Agents antiallergiques
• A61P 11/06 - Antiasthmatiques
• A61P 27/14 - Décongestionnants ou antiallergiques

Abrégé

Disclosed is a diagnostic model development technology for reproducing a cold sensation area based on abdominal palpation by a doctor of traditional medicine doctor, the technology procuring multiple pieces of data obtained by sketching a palpitated cold sensation area with an electronic pen on a notebook computer displaying a plurality of images captured in black and white, labeling the sketched position as ground truth to procure a semantic segmentation deep learning data set for detection in pixel units, using the data set for training that uses a deep neural network, and using a test set to verify the trained model, and deriving the final model.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
• A61B 5/01 - Mesure de la température de parties du corps
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
• G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
• G16H 20/90 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médecines alternatives, p.ex. l’homéopathie ou les médecines orientales

Abrégé

Disclosed is a technique related to a device assisting an abdominal examination conducted in oriental medicine. An abdominal examination index is determined on the basis of an oriental medicine abdominal examination model which has, as an input, a measurement value of a patient's abdomen. An oriental medicine abdominal examination device may, from characteristic variable values of three or more different domains, calculate, and output, probability values for a plurality of abdominal examination indexes, on the basis of the oriental medicine abdominal examination model. The abdominal examination indexes may be determined on the basis of the oriental medicine abdominal examination model which has, as inputs, measurement values obtained from a plurality of types of sensors in a plurality of regions of the patient's abdomen.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
• A61B 5/01 - Mesure de la température de parties du corps
• G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
• G16H 20/90 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médecines alternatives, p.ex. l’homéopathie ou les médecines orientales
• A61B 7/04 - Stéthoscopes électriques
• G16H 20/30 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies ou des activités physiques, p.ex. la physiothérapie, l’acupression ou les exercices

Abrégé

The present invention relates to a composition for the prevention, amelioration or treatment of poor ovarian responders caused by aging, comprising, as an active ingredient, a mixed medicinal herb extract consisting of Rehmannia glutinosa var. purpurea, Paeonia lactiflora, Cnidium officinale, and Angelica gigas, and statistically significant increases in the number of antral follicles and the number and quality of mature oocytes were confirmed in 40-week-old mice corresponding to humans of 40 years old or older, to which the mixed medicinal herb extract was orally administered. In women, the number of primordial follicles in the ovary continues to decrease with aging, and moreover, the number of antral follicles, which is the stage right before ovulation, decreases. As a result, the number of ovulating healthy mature oocytes (MII oocytes) decreases, thus gradually reducing the possibility of pregnancy. The mixed medicinal herb extract of the present invention can improve the number of antral follicles and the number and quality of mature oocytes, and thus has the effect of increasing the chance of getting pregnant in older women.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23L 5/20 - Préparation ou traitement des aliments ou produits alimentaires en général; Aliments ou produits alimentaires ainsi obtenus; Leurs matériaux Élimination de constituants indésirables, p.ex. désodorisation ou détoxication
• A61K 36/804 - Rehmannia
• A61K 36/65 - Paeoniaceae (famille de la pivoine), p.ex. pivoine chinoise
• A61K 36/234 - Cnidium (snowparsley)
• A61K 36/232 - Angelica
• A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p.ex. inducteurs d'ovulation ou de spermatogénèse

Abrégé

The present invention relates to a composition for promoting uric acid excretion, comprising an herbal complex extract as an active ingredient. The herbal complex extract not only reduces uric acid levels in the blood and increases uric acid levels in urine, but also has the effect of increasing fractional excretion of uric acid, the effect of reducing the expression of URAT1 and GLUT9, which are transporters associated with the reabsorption of uric acid, in the kidney which is a major organ for uric acid excretion, and the effect of inhibiting the reabsorption of uric acid mediated by URAT1, and thus may be usefully employed as a health functional food for promoting uric acid excretion, or as medicine for treating hyperuricemia caused by decreased uric acid excretion.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23L 19/00 - Produits à base de fruits ou de légumes; Leur préparation ou leur traitement
• A23L 5/20 - Préparation ou traitement des aliments ou produits alimentaires en général; Aliments ou produits alimentaires ainsi obtenus; Leurs matériaux Élimination de constituants indésirables, p.ex. désodorisation ou détoxication
• A61K 36/896 - Liliaceae (famille du lis), p.ex. hémérocalle, hosta, jacinthe ou narcisse
• A61K 36/79 - Schisandraceae (famille du Schisandra)
• A61K 36/258 - Panax (ginseng)
• A61P 19/06 - Agents antigoutte, p.ex. agents antihyperuricémiants ou uricosuriques

Abrégé

The present invention relates to antiviral use against coronavirus, including an Epimedium koreanum extract or a fragment thereof and, more particularly, to: an antiviral pharmaceutical composition against coronavirus, including an Epimedium koreanum extract or a fraction thereof; a pharmaceutical composition for the prevention or treatment of coronavirus infection disease; a method for the prevention or treatment of coronavirus infection disease with the pharmaceutical composition; a health functional food composition for the prevention or treatment of coronavirus infection disease, including an Epimedium koreanum extract or a fragment thereof; and a feed composition for the prevention or treatment of coronavirus inflection disease, including an Epimedium koreanum extract or a fraction thereof. The Epimedium koreanum extract of the present invention exhibits an inhibitory effect on inflection by coronaviruses such as MERS-coronavirus, SARS-coronavirus, and SARS-coronavirus-2, and thus, can be utilized in the development of antiviral drugs for the prevention or treatment of the viral diseases.

Classes IPC  ?

• A61K 36/296 - Epimedium
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

The present invention relates to the antiviral use against coronavirus, comprising a Gynostemma pentaphyllum extract or a fraction thereof and, more particularly, to: an antiviral pharmaceutical composition against coronavirus, comprising a Gynostemma pentaphyllum extract or a fraction thereof; a pharmaceutical composition for preventing or treating coronavirus infectious diseases; a method for preventing or treating coronavirus infectious diseases by means of the pharmaceutical composition; a functional health food composition for preventing or relieving coronavirus infectious diseases, comprising a Gynostemma pentaphyllum extract or a fraction thereof; and a feed composition for preventing or relieving coronavirus infectious diseases, comprising a Gynostemma pentaphyllum extract or a fraction thereof. The Gynostemma pentaphyllum extract of the present invention shows an inhibitory effect against an infection of coronavirus such as MERS-coronavirus, SARS-coronavirus and SARS-coronavirus-2, and thus can be used for developing an antiviral agent for preventing or treating the viral diseases.

Classes IPC  ?

• A61K 36/424 - Gynostemma
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

The present invention relates to an antiviral use of a natural product mixed extract or a fraction thereof against coronaviruses and, more specifically, to an antiviral pharmaceutical composition against coronaviruses, a pharmaceutical composition for prevention or treatment of coronavirus infection diseases, each pharmaceutical composition comprising a natural product mixed extract or a fraction thereof, a method for prevention or treatment of coronavirus infection diseases by using the pharmaceutical composition, a health functional food composition comprising a natural product mixed extract or a fraction thereof for prevention or alleviation of coronavirus infection diseases, and a feed composition comprising a natural product mixed extract or a fraction thereof for prevention or alleviation of coronavirus infection diseases. The natural product mixed extract of the present invention exhibits the effect of inhibiting the infection of coronaviruses such as MERS coronavirus, SARS coronavirus, and SARS coronavirus 2 and as such, can be used for developing an antiviral agent for preventing or treatment of the viral diseases.

Classes IPC  ?

• A61K 36/23 - Apiaceae ou Umbelliferae (famille de la carotte), p.ex. aneth, cerfeuil, coriandre ou cumin
• A61K 36/234 - Cnidium (snowparsley)
• A61K 36/232 - Angelica
• A61K 36/65 - Paeoniaceae (famille de la pivoine), p.ex. pivoine chinoise
• A61K 36/63 - Oleaceae (famille de l'olive), p.ex. jasmin, lilas ou frêne
• A61K 36/534 - Mentha (menthe)
• A61K 36/17 - Gnetophyta, p.ex. Ephedraceae (famille du camillo du Texas)
• A61K 36/28 - Asteraceae ou Compositae (famille de l'aster ou du tournesol), p.ex. camomille, chrysanthème matricaire, achillée ou echinacée
• A61K 36/70 - Polygonaceae (famille du sarrasin), p.ex. chorizanthe pungens ou patience
• A61K 33/06 - Aluminium, calcium ou magnésium; Leurs composés

Abrégé

The present invention relates to an antiviral use against coronavirus, comprising a Hovenia dulcis Thunb extract or a fraction thereof and, more specifically, to an antiviral pharmaceutical composition against coronavirus, comprising a Hovenia dulcis Thunb extract or a fraction thereof, a pharmaceutical composition for prevention or treatment of coronavirus infectious disease, a method for preventing or treating coronavirus infectious disease by using the pharmaceutical composition, a health functional food for prevention or amelioration of coronavirus infectious disease, comprising a Hovenia dulcis Thunb extract or a fraction thereof, and a feed composition for prevention or amelioration of coronavirus infectious disease, comprising a Hovenia dulcis Thunb extract or a fraction thereof. The Hovenia dulcis Thunb extract of the present invention exhibits an effect of inhibiting infection by coronaviruses such as MERS-coronavirus, SARS-coronavirus and SARS-coronavirus-2, and thus can be used to develop an antiviral agent for preventing or treating the viral disease.

Classes IPC  ?

• A61K 36/72 - Rhamnaceae (famille de la bourdaine), p.ex. bourdaine, jujubier ou schefflera
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

The present invention relates to a composition for preventing or treating a cognitive disorder, comprising an Iris lactea extract or a fraction thereof, and, particularly, to: a pharmaceutical composition for preventing or treating a cognitive disorder, comprising an Iris lactea extract or a fraction thereof as an active ingredient; a food composition; a feed composition; and a method for treating a cognitive disorder using the pharmaceutical composition. The Iris lactea extract of the present invention shows an excellent normalization effect and memory enhancement effect with respect to a damage to the brain such as basal forebrain, white matter, and hippocampus, and, thus, can be effectively used for treatment of a cognitive disorder related to memory disorders and cerebrovascular disorders induced by the damage, such as vascular dementia and cerebral infarction.

Classes IPC  ?

• A61K 36/88 - Liliopsida (monocotylédones)
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons

Abrégé

A method for treating sleep disturbance according to an embodiment of the present disclosure includes administering to a subject in need thereof a composition including saponarin of Chemical Formula 1, a salt thereof acceptable for use in food, or a hydrate thereof as an effective component: In an animal model with lack of sleep caused by caffeine, saponarin of the present invention restores the travel distance, mobility time, mobility frequency, and immobility time to normal as well as increases the mRNA expression of neuropeptide Y, cholecystokinin, and GABA A α1 receptor, thereby alleviating sleep disturbance. Therefore, the saponarin of the present invention can be advantageously used as a raw material for a functional health food or a pharmaceutical product for preventing, alleviating, or treating sleep disturbance.

Classes IPC  ?

• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23L 33/125 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon

Abrégé

The present invention relates to a composition for inhibiting anticancer-agent-induced ovotoxicity, containing a mixed extract of medicinal herbs as an active ingredient. Administration of a mixed extract of medicinal herbs, in combination with anticancer agent administration, has the effects of inhibiting a decrease in the number or quality of ova, caused by side effects of anticancer agents, increasing development capability of a blastocyst before implantation, and enhancing implantability in the body. Therefore, the mixed extract of medicinal herbs of the present invention can be effectively used as an anticancer adjuvant for inhibiting anticancer-agent-induced ovotoxicity.

Classes IPC  ?

• A61K 36/804 - Rehmannia
• A61K 36/65 - Paeoniaceae (famille de la pivoine), p.ex. pivoine chinoise
• A61K 36/234 - Cnidium (snowparsley)
• A61K 36/232 - Angelica
• A61P 35/00 - Agents anticancéreux
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

The present invention relates to a composition comprising an Anethum graveolens extract as an active ingredient for prevention, alleviation, or treatment of bone diseases. The Anethum graveolens extract has the effect of inhibiting the differentiation of osteoclasts and increasing the bone density and bone volume of spongy bones in ovariectomized animal models without reducing the viability of osteoclast progenitor cells. Therefore, the Anethum graveolens extract of the present invention can be advantageously used as a health functional food or medicine for prevention, alleviation, or treatment of bone diseases.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/23 - Apiaceae ou Umbelliferae (famille de la carotte), p.ex. aneth, cerfeuil, coriandre ou cumin
• A61P 19/00 - Médicaments pour le traitement des troubles du squelette

Abrégé

A method for treating sleep disturbance according to an embodiment of the present disclosure includes an extract of Fraxinus sp. plant as an effective component. As the extract of Fraxinus rhynchophylla of the present invention has an effect of ameliorating sleep disturbance by increasing the mRNA expression level of calretinin, neuropeptide Y, GAD65 and GAD67 in an animal model which has sleep disturbance caused by stress, it can be advantageously used as a raw material of a functional health food or a pharmaceutical product for preventing, ameliorating, or treating sleep disturbance.

Classes IPC  ?

• A61K 36/63 - Oleaceae (famille de l'olive), p.ex. jasmin, lilas ou frêne
• A61P 25/20 - Hypnotiques; Sédatifs
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

The present invention relates to a composition for preventing, alleviating, or treating bone diseases, containing a Mentha arvensis extract as an active ingredient. The Mentha arvensis extract has the effects of inhibiting the differentiation of osteoclasts and promoting the differentiation of osteoblasts, increasing the survival rate of osteoclast precursor cells, and increasing the bone mineral density and bone volume of trabecular bone in an ovariectomized animal model. Therefore, the Mentha arvensis extract of the present invention can be effectively used as a health functional food or a medicine for preventing, alleviating, or treating bone diseases.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/534 - Mentha (menthe)
• A61P 19/00 - Médicaments pour le traitement des troubles du squelette
• C12N 5/077 - Cellules mésenchymateuses, p.ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires

Abrégé

The present invention relates to a composition for preventing, alleviating, or treating bone diseases, containing an Euonymus sp. plant extract as an active ingredient, wherein the Euonymus sp. plant extract has the effects of inhibiting osteoclast differentiation and promoting osteoblast differentiation. Therefore, an Euonymus sp. plant extract according to the present invention can be effectively used as a health functional food or medicine for preventing, alleviating, or treating bone diseases.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/37 - Celastraceae (famille du bourreau des arbres ou de la camarine), p.ex. tripterygium ou fusain
• A61P 19/00 - Médicaments pour le traitement des troubles du squelette
• C12N 5/077 - Cellules mésenchymateuses, p.ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires

Abrégé

The present invention relates to a composition for preventing, alleviating, or treating allergic skin diseases comprising, as an active ingredient, an extract of Gardenia fruit from which pigment is removed, and since the extract of Gardenia fruit from which pigment is removed is more effective for allergic skin diseases compared to an extract of Gardenia fruit from which pigment is not removed, the composition can be very advantageously used for allergic skin diseases, in particular, atopic dermatitis.

Classes IPC  ?

• A61K 36/744 - Gardenia
• A61P 17/04 - Antiprurigineux
• A61P 37/08 - Agents antiallergiques
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23L 33/00 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement
• A23L 5/20 - Préparation ou traitement des aliments ou produits alimentaires en général; Aliments ou produits alimentaires ainsi obtenus; Leurs matériaux Élimination de constituants indésirables, p.ex. désodorisation ou détoxication
• B01D 11/02 - Extraction par solvants de solides
• B01D 15/12 - Adsorption sélective, p.ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement relatives à la préparation de l'alimentation

Abrégé

The present invention relates to a screening composition, comprising a CoV RdRp expression vector and a bicistronic reporter vector, for a therapeutic agent for coronavirus infection, a screening kit, comprising the composition, for a therapeutic agent for coronavirus infection, and a method for screening a therapeutic agent for coronavirus infection by using the composition or kit. The screening composition for a therapeutic agent for coronavirus infection, provided by the present invention, can be used to screen candidate materials having direct influences on the activity of CoV RdRp, more quickly and easily, thus finding wide applications in the development of a therapeutic agent for coronavirus infection.

Classes IPC  ?

• C12N 15/66 - Méthodes générales pour insérer un gène dans un vecteur pour former un vecteur recombinant, utilisant le clivage et la ligature; Utilisation de linkers non fonctionnels ou d'adaptateurs, p.ex. linkers contenant la séquence pour une endonucléase de restriction
• C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
• C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
• G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique

Abrégé

The present invention relates to an alimentotherapy technique by which a therapeutic effect is obtained through food. A method for an alimentotherapy information system to manage alimentotherapy information comprises: receiving an input of ancient literature material including past alimentotherapy literature and culinary literature; extracting original information from the input ancient literature material, wherein the original information includes herbal medicine information for alimentotherapy and food information required for cooking; generating ingredient information, including site of activity, processing method, blending composition, medicinal properties and effectiveness, administration method, etc., from the extracted original information, and many-to-many matching foods to the medicines, wherein the original information is integrated on the basis of a single subject matter; and refining the alimentotherapy information of the integrated original information so as to conform to modern safety standards by referencing modern medical information, food ingredient compositions, and safety information.

Classes IPC  ?

• G16H 20/60 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant le contrôle de l’alimentation, p.ex. les régimes
• G16H 70/60 - TIC spécialement adaptées au maniement ou au traitement de références médicales concernant des pathologies
• G16H 20/90 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médecines alternatives, p.ex. l’homéopathie ou les médecines orientales
• G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p.ex. pour s’assurer de l’administration correcte aux patients
• G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p.ex. pour analyser les cas antérieurs d’autres patients
• G06F 40/205 - Analyse syntaxique
• G06F 40/10 - Traitement de texte
• G16H 80/00 - TIC spécialement adaptées pour faciliter la communication entre les professionnels de la santé ou les patients, p.ex. pour le diagnostic collaboratif, la thérapie collaborative ou la surveillance collaborative de l’état de santé

Abrégé

The present invention relates to a composition for relieving a hangover, containing Pediococcus inopinatus as an active ingredient. Specifically, Pediococcus inopinatus WiKim0108 not only has no cytotoxicity, but also reduces the content of ethanol and acetaldehyde in blood that has been increased by ingestion of alcohol, effectively increases ADH and ALDH activity in the blood, and has a gastrointestinal protective function. Thus, the composition of the present invention can be effectively used as a functional health food or medicine for hangover relief or alcoholic gastrointestinal diseases.

Classes IPC  ?

• A23L 33/10 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs
• A23L 33/135 - Bactéries ou leurs dérivés, p.ex. probiotiques
• A61K 35/744 - Bactéries lactiques, p.ex. entérocoques, pédiocoques, lactocoques, streptocoques ou leuconostoques
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques

Abrégé

The present invention relates to a composition for preventing, alleviating, or treating arteriosclerosis, containing Cannabis sativa L. stem extract as an active ingredient. It has been identified that a Cannabis sativa L. stem extract shows almost no cytotoxicity and reduces the amount of intracellular lipid and the expression of cholesterol biosynthesis pathway-related genes and increases the expression of genes for discharging cholesterol. Therefore, it is expected that a Cannabis sativa L. stem extract, which is an active ingredient of the present invention, is effectively usable as a composition for preventing, alleviating, or treating arteriosclerosis.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/185 - Magnoliopsida (dicotylédones)
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
• A23L 19/00 - Produits à base de fruits ou de légumes; Leur préparation ou leur traitement
• A23L 5/20 - Préparation ou traitement des aliments ou produits alimentaires en général; Aliments ou produits alimentaires ainsi obtenus; Leurs matériaux Élimination de constituants indésirables, p.ex. désodorisation ou détoxication

Abrégé

The present invention relates to a composition for preventing, alleviating or treating androgen-dependent diseases, containing a bamboo leaf extract as an active ingredient. Compared to other types of bamboo extracts, a bamboo leaf extract of the present invention significantly reduces the expression level of a SRD5A2 gene that codes for 5α-reductase, is hardly cytotoxic, reduces the weight of the prostate, reduces the proliferation of prostate tissue epidermal cells, and reduces the amounts of serum testosterone, dihydrotestosterone, PSA and SRD5A2, thereby being effectively usable for androgen-dependent diseases.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/899 - Poaceae ou Gramineae (famille des céréales), p.ex. bambou, blé ou canne à sucre
• A61P 5/24 - Médicaments pour le traitement des troubles du système endocrinien des hormones sexuelles
• A61K 8/9794 - Liliopsida [monocotylédones]
• A61Q 7/00 - Préparations pour modifier la pousse des cheveux ou des poils
• A23L 19/00 - Produits à base de fruits ou de légumes; Leur préparation ou leur traitement

Abrégé

The present invention relates to a composition for preventing, ameliorating or treating an androgen-dependent disorder comprising Phyllostachys pubescens extract as an effective component. It was found that, compared to the extracts of other types of bamboo, the Phyllostachys pubescens extract of the present invention can significantly reduce the expression amount of the SRD5A2 gene which encodes 5?-reductase while hardly showing any cytotoxicity. The composition of the present invention was found to have effects that can reduce the prostate weight, reduce the proliferation of epithelial cells in prostate tissues, and also can reduce the content of testosterone, dihydrotestosterone, PSA, and SRD5A2 in blood serum. Thus, the composition of the present invention can be advantageously used for an androgen-dependent disorder.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 8/9794 - Liliopsida [monocotylédones]
• A61K 36/899 - Poaceae ou Gramineae (famille des céréales), p.ex. bambou, blé ou canne à sucre
• A61P 5/24 - Médicaments pour le traitement des troubles du système endocrinien des hormones sexuelles

Abrégé

The present invention relates to: a vaccine immune adjuvant composition containing bavachin as an active ingredient, the composition enabling antibody titer to be improved when administered with an antigen and cellular immunity and humoral immunity to be enhanced; a vaccine formulation containing bavachin and an antigen; a method for promoting immune responses, comprising a step of administering an individual with both the vaccine immune adjuvant composition and a vaccine composition or before or after administration of the vaccine composition; and a vaccine adjuvant composition for promoting immune responses, containing bavachin. A vaccine immune adjuvant composition of the present invention contains bavachin isolated from a Psoraleae semen extract of which the safety is ensured, and thus is safe, and can enhance the titer of an antibody produced according to an antigen and both humoral immunity and cellular immunity, thereby being widely usable in the development of an effective vaccine formulation.

Classes IPC  ?

• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
• A61K 31/353 - 3,4-Dihydrobenzopyranes, p.ex. chromane, catéchine
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

Hibiscus syriacus extract as an effective ingredient as an effective ingredient can be advantageously used as a functional health food composition or a pharmaceutical composition for preventing, ameliorating or treating sleeping disorders.

Classes IPC  ?

• A61K 36/185 - Magnoliopsida (dicotylédones)
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61P 25/20 - Hypnotiques; Sédatifs

Abrégé

A Sikchijeho-tang composition of the present invention exhibits a blood circulation-enhancing effect as high as or higher than that of Gagamjeho-tang comprising a smoky Prunus mume fruit, a Amomum villosum LOUR. fruit, an Amomum tsao-ko fruit, and a Pterocarpus santalinus stem and is free of an Amomum tsao-ko fruit and a Pterocarpus santalinus stem, which are both prohibited from being used as foods, and employs either Agastache rugosa or Agastache rugosa and Citrus maxima, whereby the composition can be industrially prepared into foods, beverages, and medicinal products.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23L 2/04 - Extraction des jus
• A23L 2/08 - Concentration ou dessiccation des jus
• A23L 21/25 - Miel; Succédanés du miel
• A23L 19/00 - Produits à base de fruits ou de légumes; Leur préparation ou leur traitement
• A61K 36/736 - Prunus, p.ex. prune, cerise, pêche, abricot ou amande
• A61K 36/906 - Zingiberaceae (famille du gingembre)
• A61K 36/532 - Agastache, p.ex. hysope
• A61K 36/752 - Citrus, p.ex. citron vert, orange ou citron
• A61P 7/02 - Agents antithrombotiques; Anticoagulants; Anti-agrégants plaquettaires

Abrégé

Disclosed are a method for assessing degenerative cognitive decline on the basis of eye movement and an apparatus for evaluating degenerative cognitive decline on basis of eye movement. According to one embodiment of the present invention, a method for evaluating degenerative cognitive decline on the basis of eye movement comprises the steps of: analyzing forward and reverse saccadic eye movements of eyeballs for tracking a moving target; measuring an error rate regarding a degree of deviation of the movement of the eyeballs from the movement path of the target through the analysis; measuring a response delay time required for the eyeballs to track the target in a predetermined interval in which the target moves through the analysis; and when any one of the error rate and the response delay time is greater than or equal to a predetermined threshold value, determining that a subject who recognizes an object through the eyeballs has cognitive decline.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
• A61B 5/16 - Dispositifs pour la psychotechnie; Test des temps de réaction
• A61B 3/113 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour déterminer ou enregistrer le mouvement de l'œil
• A61B 3/11 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour mesurer la distance interpupillaire ou le diamètre de la pupille

Abrégé

The present invention relates to a composition for preventing or ameliorating Alzheimer's dementia, comprising a Tetragonia teragonioides extract as an active ingredient. By using this, accumulation of β-amyloids in the brain tissue is prevented, expression of brain-derived neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF) genes is increased, and expression of Tau genes forming neurofibrillary tangles (MTF), known as a cause of Alzheimer's dementia, is reduced, thereby preventing, ameliorating or treating Alzheimer's dementia, specifically of β-amyloid accumulation type and Tau protein accumulation type.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/185 - Magnoliopsida (dicotylédones)
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

The present invention relates to a composition, comprising a Salvia plebeia R. Br. extract as an active ingredient, for inhibiting tumor growth. A Salvia plebeia R. Br. extract was found to bind to PD-L1 present on cancer cell surfaces to block the interaction of cancer cells with PD-1 on the surface of immune T cells, thereby activating T cells to show a suppressive effect on tumor growth. When T cells were cocultured with colorectal cancer, breast cancer, or lung cancer cells, an effect of killing cancer cells was found to be improved in a Salvia plebeia R. Br. extract-treated group.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/537 - Salvia (sauge)
• A61K 39/395 - Anticorps; Immunoglobulines; Immunsérum, p.ex. sérum antilymphocitaire
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur 
• A61P 35/00 - Agents anticancéreux
• A61P 31/04 - Agents antibactériens
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

Provided is a composition for preventing or treating obesity including a mixed extract of Cinnamomi twigs, and more particularly, a pharmaceutical composition for preventing or treating obesity including a mixed extract of Cinnamomi twigs and Moutan root bark, a health functional food composition of feed composition for preventing or alleviating obesity including the composition, and a method of preventing or treating obesity including administering the pharmaceutical composition to an individual having obesity or a risk of developing obesity. The mixed extract of Cinnamomi twigs and Moutan root bark may inhibit fat absorption in the intestinal tract and increases in body weight causing obesity by single-dose administration, reduce lipid content in the blood, decrease weight and size of adipocytes, effectively inhibit accumulation of fat in liver tissue, and inhibit diarrhea, a serious side effect of Xenical™, by long-term administration.

Classes IPC  ?

• A61K 36/65 - Paeoniaceae (famille de la pivoine), p.ex. pivoine chinoise
• A23L 33/00 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61P 3/04 - Anorexigènes; Médicaments de l'obésité
• A61K 36/54 - Lauraceae (famille du laurier), p.ex. cannelle ou sassafras

Abrégé

The present invention relates to a three-dimensional face image capturing method and comprises the steps of: capturing a face region of a user in a direction from a right chin to a left forehead; capturing the face region in a direction from a left forehead to a left chin; capturing the face region in a direction from a left chin to a right forehead; and capturing the face region in a direction from a right forehead to a center of face.

Classes IPC  ?

• H04N 13/221 - Générateurs de signaux d’images utilisant des caméras à images stéréoscopiques utilisant un seul capteur d’images 2D utilisant le mouvement relatif de caméras et de sujets
• G06T 7/579 - Récupération de la profondeur ou de la forme à partir de plusieurs images à partir du mouvement

Abrégé

The present invention relates to a pharmaceutical composition for use in the prevention or treatment of a degenerative brain disease or a composition for use in neuroprotection, comprising a Periostracum Cicadae extract. In addition, the present invention relates to a method for preventing or treating a degenerative brain disease, comprising the step of administering a Periostracum Cicadae extract to a patient with the degenerative brain disease. The Periostracum Cicadae extract of the present invention amplifies neurotrophic factors or dopamine by increasing the activity of Nurr1 proteome, and has a neuroprotection effect by inhibiting neuronal cell death or nerve inflammation, thereby ameliorating behavior disorders caused by a degenerative brain disease such as Parkinson's disease, and furthermore can be expected to have the effect of ameliorating lowering of concentration, ADHD, schizophrenia, depression, or manic depression resulting from a dopamine decrease.

Classes IPC  ?

• A61K 35/64 - Insectes, p.ex. abeilles, guêpes ou puces
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A23L 33/10 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs

Abrégé

The present invention relates to a composition that comprises a preparation that measures the methylation level of the promoter region of the natriuretic peptide receptor 2 (NPR2) gene, and thus can predict or diagnose hypertension or obesity even when a symptom thereof is not identified visually or from other results, or even at a very early stage.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The present invention relates to a skin-whitening composition comprising a royal azalea root extract as an effective component. More specifically, the royal azalea root extract has no cytotoxicity, and compared to other parts (leaves, stems, and flowers), the root part was found to have a high tyrosinase inhibition activity and show a significant melanogenesis inhibitory activity. Therefore, the skin-whitening composition of the present invention may be utilized as a functional material for whitening and lightening of the skin.

Classes IPC  ?

• A61K 8/9789 - Magnoliopsida [dicotylédones]
• A61Q 19/02 - Préparations pour les soins de la peau pour décolorer ou blanchir la peau chimiquement
• A61K 36/45 - Ericaceae ou Vacciniaceae (famille de la bruyère ou de la myrtille), p.ex. myrtille, canneberge ou airelle
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

22, lowers ALT levels in an animal model in which a fatty liver has been induced by a high-fat diet, decreases liver weight, and downregulates the expression level of a fat metabolism-related gene in the liver, thereby finding advantageous applications as a health functional food, a medicine, a feed additive, or a veterinary composition for prevention, alleviation, or treatment of fatty liver disease.

Classes IPC  ?

• A23L 33/135 - Bactéries ou leurs dérivés, p.ex. probiotiques
• A61K 35/744 - Bactéries lactiques, p.ex. entérocoques, pédiocoques, lactocoques, streptocoques ou leuconostoques
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A23K 10/16 - Ajout de micro-organismes ou de leurs produits d’extraction, p.ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires
• C12N 1/20 - Bactéries; Leurs milieux de culture
• C12R 1/46 - Streptococcus

Abrégé

22), reducing ALT and TG content in blood which has been increased by alcohol, lowering ALT levels in an animal model in which fatty liver has been induced through a high-fat diet, reducing the weight of the liver, and reducing the expression level of a lipid metabolism-associated gene in the liver, and thus the composition of the present invention may be usefully employed as a health functional food, medicine, feed additive or veterinary composition for preventing, improving or treating fatty liver disease.

Classes IPC  ?

• A23L 33/135 - Bactéries ou leurs dérivés, p.ex. probiotiques
• A61K 35/744 - Bactéries lactiques, p.ex. entérocoques, pédiocoques, lactocoques, streptocoques ou leuconostoques
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A23K 10/16 - Ajout de micro-organismes ou de leurs produits d’extraction, p.ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires
• C12N 1/20 - Bactéries; Leurs milieux de culture
• C12R 1/01 - Bactéries ou actinomycètes

Abrégé

The present invention relates to a composition which is for preventing, ameliorating, or treating andropause, and comprises a vitex trifolia extract as an active ingredient. The vitex trifolia extract, which is the active ingredient of the present invention, has almost no cytotoxicity, and has a cytoprotective activity on damaged sex hormone-secreting cells. Moreover, the vitex trifolia extract has the effects of: increasing the content of testosterone; increasing the expression of 17β-HSD in male hormone-secreting cells; reducing cholesterol and blood glucose; increasing the weight of the vastus lateralis (VL); reducing the weight of fat in the epididyma fat (EF) portion of visceral fat; reducing the weight of fat in the mescentric fat (MF) portion and the weight of fat in the abdominal subcutaneous fat (ASF) portion; decreasing immobility behavior time and increasing swimming behavior time and climbing behavior time in the forced swimming test (FST); and also increasing sperm count and sperm activity. Thus, the composition according to the present invention can be used as a health functional food or medicine for preventing, ameliorating, or treating andropause.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/85 - Verbenaceae (famille de la verveine)
• A61P 5/24 - Médicaments pour le traitement des troubles du système endocrinien des hormones sexuelles